Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 100, Issue 1, 2006, Pages 3-4

  Trimble, Edward L ^a   Christian, Michaele C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; EDITORIAL; FEMALE; GYNECOLOGIC SURGERY; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 29144478668     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.12.006     Document Type: Editorial

References (8)

1. Walker JL, Armstrong D, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase II trial of intravenous versus intraperitoneal chemotherpy in optimal stage II ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol (in press).
2. Armstrong DK, Bundy B, Wenzel L, et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in stage III ovarian carncer: a Gynecologic Oncology Group study. New Engl J Med (in press).
3. D.S. Alberts, P.Y. Liu, and E.V. Hannigan Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N. Engl. J. Med. 335 1996 1950 1955
4. M. Markman, B.N. Bundy, and D.S. Alberts Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J. Clin. Oncol. 19 2001 1001 1007
5. M.J. Piccart, A. Floquet, and G. Scarfone Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy Int. J. Gynecol. Cancer 13 Suppl 2 2003 196 203
6. http://www.cancer.gov.
7. R.E. Bristow, R.S. Tomacruz, and D.K. Armstrong Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J. Clin. Oncol. 20 2002 1248 1259
8. http://ctep.cancer.gov/resources/gcig/.